Retatrutide + GHK-Cu
No trial has tested these two together, and the skin problem people are trying to solve is mostly elastin.
The reason people pair these is specific and reasonable: retatrutide produces the largest weight loss any drug has published, and loose skin is the thing they are told to expect. GHK-Cu is the peptide most associated with collagen. The difficulty is that stretched skin is a collagen problem and an elastin problem, and adult skin barely makes new elastin.
Losing the weight, and dreading the skin.
The worry behind this pairing is a real one, and the people raising it are not being irrational. Someone watching 30 kilograms come off over eighteen months has a reasonable question about what the skin will do. The internet has told them the answer is loose folds that only surgery removes.
GHK-Cu is the obvious thing to reach for. It has four decades of research behind it, most of that research is about collagen and tissue repair, and collagen is what people understand firmness to be made of.
The combination comes up in weight loss communities rather than in bodybuilding ones. That fits the motivation. We found discussion of it across the retatrutide and biohacking subreddits, and the signal is real without being large.[1]
No trial has tested the two compounds together, in any population, for any outcome. Nothing published measures what injected GHK-Cu does to skin during or after rapid weight loss.
Four benefits, and how well each one holds up.
The second row is genuine and it describes a different problem from the third. Facial wrinkle depth over eight weeks and a hanging abdominal fold after 30 kilograms are not the same measurement.
Three questions, answered before anything else.
Collagen rebuilds. Elastin mostly does not.
Skin holds its shape through two different proteins in the dermis. Collagen supplies strength and structure. Elastin supplies the recoil, the property that lets skin return toward its previous shape after being stretched.
Those two proteins behave very differently over a lifetime. Fibroblasts keep producing collagen into adulthood, at a declining rate. Elastin is close to a fixed inheritance. Its production falls away once growth ends, and racemization studies show the elastin in adult skin was laid down decades earlier with minimal turnover since.[2][3]
One clinical review puts it flatly: there are established treatments that raise collagen in skin and none that increase elastin production.[3]
That matters for this stack because of what biopsy work has found in people after massive weight loss. Skin samples showed lower collagen density and thickness together with damaged elastic fibers, and a shift away from thick organized collagen bundles toward thin, misaligned ones.[4][5]
GHK-Cu's documented action is weighted heavily toward the half of that problem the body can already address. Signaling for more collagen in skin whose elastic fibers are damaged is working on the component that was never the limiting one. Our guide on what happens to skin after significant weight loss covers what has and has not been shown to change it.
There is a reasonable objection to that argument and it deserves stating. GHK-Cu incubated with human adult dermal fibroblasts increased the production of elastin as well as collagen, at concentrations from 0.01 to 100 nanomolar.[6] The 2016 wrinkle trial was titled for collagen and elastin production, so the researchers were looking at both.[7]
Cells in a dish producing tropoelastin is a different claim from damaged elastic fibers in adult skin being rebuilt and cross-linked into a working network. No human study has measured elastin in skin after GHK-Cu by any route, and none has measured it after weight loss. The in vitro signal is real, and it is a reason to want the study rather than a substitute for it.
Real trials, and all of them topical.
GHK-Cu is not a weak compound, and dismissing it would be wrong. It has more than four decades of preclinical evidence for tissue regeneration and gene expression remodelling, and genuine controlled human studies.[8]
Those human studies share a shape. A 2016 randomized double-blind trial followed 40 women aged 40 to 65 using a topical formulation over eight weeks, measuring wrinkle depth and volume.[7] Others have measured facial laxity, firmness, density and thickness over periods counted in weeks.[7]
Every one of them applied the compound to skin. Reporting in September 2026 found no published human study showing injected GHK-Cu to be safe or effective, against decades of small topical trials,[9] and a 2026 review of the chemistry places injectable copper-peptide products sold outside an approved marketing authorization outside any defined evidentiary or quality framework.[10] A 2026 systematic review of microneedle delivery makes a similar point about that route, noting it has yet to be evaluated in a single registered, adequately powered human randomized trial.[8]
Our guide on the three different products sold as GHK-Cu goes through the route question properly. The short version for this page is that the evidence people cite when buying vials was generated by a cream.
Vendor pages routinely bridge that gap with confidence. One states that injectable GHK-Cu delivers significantly higher bioavailability and typically produces more pronounced results for established skin laxity. That is a claim about a route with no trials behind it.
What retatrutide's trial produced.
The concern behind this stack is proportionate to the weight loss, so the trial numbers are worth having in front of you.
TRIUMPH-1 randomized adults with obesity or overweight plus a weight-related condition. At 80 weeks the 12 mg arm lost 28.3 percent of body weight on average, against roughly 2 percent on placebo, from a mean baseline around 112 kilograms.[11]
The distribution matters more than the mean for this question. In that arm, 62.5 percent lost at least a quarter of their body weight, 45.3 percent lost at least 30 percent, and 27.2 percent lost at least 35 percent.[11] A prespecified extension in participants with higher starting BMI reached 30.3 percent at 104 weeks.[11]
Losing a third of your body weight over eighteen months is the kind of change that historically followed bariatric surgery, and loose skin is a well-documented consequence of that. The worry is not manufactured by vendors.
One thing the trial did not measure is body composition. Our news piece on the published TRIUMPH-1 results covers that gap, and the guide to skin changes on retatrutide covers what people report during treatment.
What is documented, and what is convention.
People running GHK-Cu alongside anything else usually encounter advice about copper. Some of that advice rests on published chemistry and some on community practice, and the two are worth separating.
Documented. Copper ions catalyze oxidation of methionine and cysteine residues, and trace copper is a known cause of degradation in protein drug formulations.[12] No stability data exists for GHK-Cu mixed with any other peptide, so separate injections avoid the question. Copper itself has a tolerable upper intake of 10 mg a day for adults from all sources, chronic excess damages the liver, and the dermatologists quoted in September 2026 described patients with raised liver enzymes and copper levels after injecting large amounts without monitoring.[13][9]
Also documented, and more recent. A September 2026 NPR report quoted a dermatologist describing patients who arrived with elevated liver enzymes and elevated copper after injecting large amounts without checking lab work. That same report notes it is unclear whether the copper peptide, other undisclosed substances, or impurities were responsible.[9] It also records that an FDA advisory panel was due to meet in February to review the evidence for GHK-Cu as an injectable.[9]
Convention. Specific stability claims about particular peptide pairings, timing rules about which compound goes first, and advice about balancing copper against zinc intake circulate widely without published data attached. The underlying chemistry is real. The specific protocols are not measured.
Neither we nor the sources we found have stability data for GHK-Cu alongside retatrutide specifically. Anyone taking both has a straightforward reason to ask a doctor about copper and liver markers rather than to work it out from forum threads.
Two vials, and no premixed version.
Nobody sells these two together, so this is two separate purchases at whatever the market is charging today. Both compounds have wide spreads, and that matters more than the floor price.
GHK-Cu also appears in several premixed blends aimed at skin and repair. The GHK-Cu and BPC-157 pairing is the cheapest route into that category, and GLOW adds TB-500 on top.
The comparison that matters is not between these two vials. Topical GHK-Cu is the form with the human trials, costs less than injectable vials in most cases, and is sold through ordinary cosmetic channels.
One drug awaiting approval, one compound under review.
Retatrutide is approved nowhere. Its Phase 3 program is complete and a US filing is planned, so everything sold online remains research chemical material.
GHK-Cu has no approval as an injectable anywhere. Topical formulations are sold as cosmetics under ordinary cosmetic rules, a different regulatory position from the vials.
An FDA advisory panel recommended reclassifying several peptides during 2026 and was scheduled to review GHK-Cu as an injectable in February.[9] That review may change what compounding pharmacies can do with it, so the position described here has a date attached to it.
For anyone losing weight at the rate TRIUMPH-1 describes, the useful conversation with a doctor is about protein intake, resistance training and the realistic timeline for skin remodelling. All three have evidence behind them. Surgeons expect some skin contraction for about a year after weight stabilizes and little after that, which is why body contouring is usually timed 12 to 18 months after a bariatric operation.[4][15]
What people ask about this stack
Does GHK-Cu prevent loose skin on retatrutide?
Nothing published has measured that. No trial has tested retatrutide and GHK-Cu together, and no study has measured GHK-Cu of any form against loose skin after major weight loss. The human evidence for GHK-Cu comes from topical trials measuring facial wrinkles, firmness and density over weeks. That is a different outcome in a different place on the body.
Why is elastin the problem rather than collagen?
Skin retracts because of elastin, and elastin is close to a fixed inheritance. Its production falls away once growth ends, and racemization studies show the elastin in adult skin was made decades earlier with minimal turnover. Collagen keeps being produced into adulthood. Biopsy work after massive weight loss finds both lower collagen density and damaged elastic fibers. A compound that signals for collagen therefore addresses the half of the problem the body was already addressing. GHK-Cu has increased elastin production in human fibroblasts in a dish. That is worth knowing, and it is not the same as rebuilding damaged fibers in skin.
Does injectable GHK-Cu have human trials?
No. Reporting in September 2026 found no published human study showing injected GHK-Cu to be safe or effective, while the topical form has decades of small human trials. A 2026 systematic review of microneedle delivery reports the same gap for that route. Vendor pages that describe injection as more effective are making a claim about a route with no trials behind it.
How much weight do people lose on retatrutide?
In TRIUMPH-1 the 12 mg arm lost 28.3 percent of body weight on average at 80 weeks, against roughly 2 percent on placebo, from a mean baseline around 112 kilograms. Within that arm, 45.3 percent lost at least 30 percent of their body weight and 27.2 percent lost at least 35 percent. Participants with higher starting BMI who continued to 104 weeks averaged 30.3 percent in a prespecified extension.
Should GHK-Cu be mixed with other peptides?
Not without stability data, and none exists. Copper ions catalyze oxidation of methionine and cysteine residues in peptides, a documented degradation route for protein drugs, so separate injections avoid the question. The specific protocols circulating about which compound goes first, or how to balance copper against zinc, are community convention without published data behind them. No stability data exists for GHK-Cu alongside retatrutide specifically.
What helps with loose skin after major weight loss?
Some retraction can be expected for about a year after weight stabilizes, with little change after that. For a substantial skin excess the evidence points to surgical removal as the only reliable option, and no supplement or peptide has been shown to shrink hanging folds. Protein intake and resistance training support the parts that are modifiable. Compare against the other stacks.
What this page is built on
- 01Community discussion of retatrutide with GHK-Cu, including r/Retatrutide, 27 September 2026 and r/Biohacking, the latter covering retatrutide with tesamorelin and GHK-Cu.
- 02Ritz-Timme S, Laumeier I, Collins MJ. Aspartic acid racemization: evidence for marked longevity of elastin in human skin. British Journal of Dermatology, 2003;149(5):951-959. PMID 14632798, DOI 10.1111/j.1365-2133.2003.05618.x. Purified elastin from human skin accumulates racemized aspartic acid in close correlation with age (r = 0.98), which the authors read as a lack of turnover and an accumulation of damage in elastin over a lifetime.
- 03Baumann L, Bernstein EF, Weiss AS, Bates D, Humphrey S, Silberberg M, Daniels R. Clinical relevance of elastin in the structure and function of skin. Aesthetic Surgery Journal Open Forum, 2021;3(3):ojab019. PMC8239663. Review. Elastin has very low turnover and its production decreases after growth; there are many interventions that raise collagen and hyaluronic acid in skin but no established treatment that increases elastin production.
- 04Sami K, Elshahat A, Moussa M, Abbas A, Mahmoud A. Image analyzer study of the skin in patients with morbid obesity and massive weight loss. Eplasty, 2015;15:e4. PMC4311578. Thirty patients. Collagen fibers were significantly thinner and less dense in the massive weight loss group, with damage to the elastic fiber network. The introduction notes that some contraction of the skin envelope can be expected for about a year after a stable weight is reached, with little change after that.
- 05Rocha RI, Cintra Junior W, Modolin MLA, Takahashi GG, Caldini ETEG, Gemperli R. Skin changes due to massive weight loss: histological changes and the causes of the limited results of contouring surgeries. Obesity Surgery, 2021;31(4):1505-1513. DOI 10.1007/s11695-020-05100-3. Epigastric skin from 20 patients after massive weight loss against 20 with morbid obesity. Fewer thick collagen fibers, more thin ones, and a shift from organized, directed bundles to thin, misaligned, loosely arranged fibers; elastic fiber density was higher, not lower.
- 06Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018. PMC6073405, PMID 29986520. Source for GHK-Cu at 0.01, 1 and 100 nanomolar incubated with human adult dermal fibroblasts increasing production of both elastin and collagen, for a facial cream applied for 12 weeks to 71 women increasing skin density and thickness and reducing laxity, for an eye cream over 12 weeks in 41 women outperforming placebo and vitamin K cream, and for GHK-Cu applied to thigh skin improving collagen production in 70 percent of women against 50 percent for vitamin C and 40 percent for retinoic acid.
- 07Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science, 2016. Record. Randomized double-blind trial, 40 female volunteers aged 40 to 65, twice-daily topical GHK-Cu in a lipid-based nano-carrier over 8 weeks, analyzed on 39. Wrinkle volume fell 55.8 percent and depth 32.8 percent against control serum, and volume fell 31.6 percent against a Matrixyl 3000 comparator. Separately, the source for human topical research having measured wrinkle appearance, laxity, firmness, density and thickness over periods counted in weeks, and for that evidence not establishing that a topical peptide removes excess tissue after major weight loss.
- 08A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. PMC13604022. Source for more than four decades of preclinical evidence on tissue regeneration and gene-expression remodelling, and for microneedle-mediated delivery not yet having been evaluated in a single registered, adequately powered human randomized controlled trial published in the peer-reviewed literature.
- 09The copper peptide trend has gone from creams to injections, ahead of the science. NPR, 7 September 2026. Article. Source for a dermatologist describing patients presenting with elevated liver enzymes and elevated copper after injecting large amounts without lab monitoring, for the accompanying caveat that attribution to the copper peptide rather than impurities or undisclosed substances is unclear, and for an FDA advisory panel having recommended reclassifying several peptides with a February meeting scheduled to review GHK-Cu as an injectable.
- 10GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics, 2026;18(9):1077. DOI 10.3390/pharmaceutics18091077. Review. States that injectable copper-peptide preparations supplied outside an approved marketing authorization sit outside any defined evidentiary or quality framework, that delivery studies commonly report total copper without resolving how much is loosely bound, and that no validated GHK-Cu-specific threshold for loosely bound copper exists.
- 11Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. New England Journal of Medicine, published online September 29, 2026. DOI 10.1056/NEJMoa2604169. TRIUMPH-1, NCT05929066: 2,339 adults with obesity or overweight and a weight-related condition, without diabetes, randomized to retatrutide 4, 9 or 12 mg or placebo for 80 weeks. Weight change on the efficacy estimand 19.0, 25.9 and 28.3 percent against 2.2 percent; at 12 mg, 62.5 percent lost at least 25 percent and 45.3 percent at least 30 percent. The baseline weight of 112.7 kg, the 27.2 percent reaching 35 percent, and the 30.3 percent at 104 weeks in a 532-participant extension of people with a starting BMI of 35 or more are from Lilly's results release of May 21, 2026, company release.
- 12Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnology and Bioengineering, 1995;48(5):490-500. DOI 10.1002/bit.260480511. Methionine, cysteine, histidine, tryptophan and tyrosine are the residues most susceptible to oxidation, and oxidation during processing and storage is catalyzed by transition metal ions. Uehara H, et al. Comparative effects of metal-catalyzed oxidizing systems on carbonylation and integrity of therapeutic proteins. Pharmaceutical Research, 2016;33(2):526-539. PMID 26499343. Trace copper above 75 parts per billion enhanced oxidative damage and aggregation of therapeutic proteins; other metals tested did not.
- 13Copper: fact sheet for health professionals. National Institutes of Health, Office of Dietary Supplements, updated October 18, 2022. NIH page. Tolerable upper intake level for adults 10,000 mcg a day from all sources; regular excess can cause liver damage and gastrointestinal symptoms.
- 14Peptide Decoding vendor pricing data. Lowest in-stock single-compound listings for retatrutide and GHK-Cu, with listing counts, computed at page load. No premixed listing combines the two compounds.
- 15Giordano S. Removal of excess skin after massive weight loss: challenges and solutions. Open Access Surgery, 2015;8. Full text. Review. Body contouring is recommended once weight is stable, 12 to 18 months after the bariatric operation and after 4 to 6 months without weight fluctuation.
